Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?

Abstract excerpt

CYP2D6 metabolizes about 20% of commonly used drugs, including tamoxifen, a major hormone therapy for breast cancer. Although the relationship between tamoxifen pharmacokinetics and CYP2D6 genotype has been demonstrated, residual variability in drug exposure remains unexplained. Given the high genetic polymorphism of CYP2D6, including copy number variations and hybrid genes, targeted genotyping may fail to...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents, Hormonal
• Breast Neoplasms
• Cytochrome P-450 CYP2D6
• Genotype
• High-Throughput Nucleotide Sequencing